Last 12 months
Inside the activity.
2 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC |
Vasista VittalChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,718 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · derivative · entry 8 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,282 Underlying: Common Stock · 9,718 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC |
Vasista VittalChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,959 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · derivative · entry 7 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,041 Underlying: Common Stock · 9,959 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC |
Vasista VittalChief Financial Officer
|
SaleCommon Stock | 19,677 | $70.04 | $1,378,177.08 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC |
Vasista VittalChief Financial Officer
|
Exercise / conversionCommon Stock | 9,718 | $13.09 | $127,208.62 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC |
Vasista VittalChief Financial Officer
|
Exercise / conversionCommon Stock | 9,959 | $3.76 | $37,445.84 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,414 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · derivative · entry 8 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,072 Underlying: Common Stock · 20,414 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 100 | $64.42 | $6,442.00 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 7 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 5,446 | $63.67 | $346,746.82 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 6 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $63.29 to $64.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 8,026 | $62.93 | $505,076.18 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 5 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $62.285 to $63.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 2,100 | $61.82 | $129,822.00 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 4 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,572 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $61.28 to $62.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 1,700 | $60.66 | $103,122.00 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 3 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,672 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $60.26 to $61.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 3,042 | $59.83 | $182,002.86 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 2 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $59.26 to $60.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:22 UTC |
Yoo StephenChief Medical Officer
|
Exercise / conversionCommon Stock | 20,414 | $0.85 | $17,351.90 |
DisclosureSEC source: 0001562180-18-004338 · primarydocument.xml · nonDerivative · entry 1 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC |
Christmas Patrick J.SVP, General Counsel
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · derivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,472 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC |
Christmas Patrick J.SVP, General Counsel
|
SaleCommon Stock | 90 | $62.67 | $5,640.30 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC |
Christmas Patrick J.SVP, General Counsel
|
SaleCommon Stock | 3,410 | $62.00 | $211,420.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $61.65 to $62.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC |
Christmas Patrick J.SVP, General Counsel
|
SaleCommon Stock | 1,500 | $61.22 | $91,830.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,169 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.63 to $61.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC |
Christmas Patrick J.SVP, General Counsel
|
Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,414 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · derivative · entry 8 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,486 Underlying: Common Stock · 10,414 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 10,414 | $61.18 | $637,128.52 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · nonDerivative · entry 6 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
Exercise / conversionCommon Stock | 10,414 | $0.85 | $8,851.90 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · nonDerivative · entry 5 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,667 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · derivative · entry 9 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 2,667 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 10,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,125 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · derivative · entry 8 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 Underlying: Common Stock · 13,125 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 46,517 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · derivative · entry 7 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,983 Underlying: Common Stock · 46,517 shares Expires 2025-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
SaleCommon Stock | 2,667 | $60.85 | $162,286.95 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 6 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
Exercise / conversionCommon Stock | 2,667 | $13.09 | $34,911.03 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 5 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
SaleCommon Stock | 13,125 | $60.85 | $798,656.25 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 4 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
Exercise / conversionCommon Stock | 13,125 | $19.50 | $255,937.50 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 3 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
SaleCommon Stock | 46,517 | $60.85 | $2,830,559.45 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 2 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2018 Filed Oct 18, 2018 20:24 UTC |
Simpson CurranSVP, Technical Operations
|
Exercise / conversionCommon Stock | 46,517 | $22.00 | $1,023,374.00 |
DisclosureSEC source: 0001562180-18-004249 · primarydocument.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:17 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 5,710 | $59.55 | $340,030.50 |
DisclosureSEC source: 0001562180-18-004240 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.17 to $60.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:17 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 1,800 | $58.73 | $105,714.00 |
DisclosureSEC source: 0001562180-18-004240 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,710 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.16 to $59.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · derivative · entry 7 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,900 Underlying: Common Stock · 10,000 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 100 | $60.25 | $6,025.00 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · nonDerivative · entry 4 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 7,000 | $59.54 | $416,780.00 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · nonDerivative · entry 3 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.18 to $60.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
SaleCommon Stock | 2,900 | $58.83 | $170,607.00 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · nonDerivative · entry 2 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.18 to $59.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:29 UTC |
Yoo StephenChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $0.85 | $8,500.00 |
DisclosureSEC source: 0001562180-18-004242 · primarydocument.xml · nonDerivative · entry 1 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:24 UTC |
Vasista VittalChief Financial Officer
|
SaleCommon Stock | 5,000 | $59.59 | $297,950.00 |
DisclosureSEC source: 0001562180-18-004241 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.34 to $59.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:24 UTC |
Vasista VittalChief Financial Officer
|
SaleCommon Stock | 2,500 | $58.93 | $147,325.00 |
DisclosureSEC source: 0001562180-18-004241 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.29 to $59.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:20 UTC |
Danos OlivierChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001562180-18-004207 · primarydocument.xml · derivative · entry 6 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:20 UTC |
Danos OlivierChief Scientific Officer
|
SaleCommon Stock | 216 | $65.60 | $14,169.60 |
DisclosureSEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 5 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.40 to $65.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:20 UTC |
Danos OlivierChief Scientific Officer
|
SaleCommon Stock | 4,000 | $64.78 | $259,120.00 |
DisclosureSEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 4 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.36 to $65.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:20 UTC |
Danos OlivierChief Scientific Officer
|
SaleCommon Stock | 12,284 | $63.73 | $782,859.32 |
DisclosureSEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 3 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,216 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.35 to $64.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:20 UTC |
Danos OlivierChief Scientific Officer
|
SaleCommon Stock | 3,500 | $62.79 | $219,765.00 |
DisclosureSEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 2 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.31 to $63.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:20 UTC |
Danos OlivierChief Scientific Officer
|
Exercise / conversionCommon Stock | 20,000 | $20.35 | $407,000.00 |
DisclosureSEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 1 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 26, 2018 Filed Jan 28, 2020 21:18 UTC |
Mills Kenneth T.Director · President and CEO
|
GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000618 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 F1 · shares: This transaction involved an irrevocable gift of securities by the Reporting Person to a charitable donor advised fund. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 20:24 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 300 | $81.12 | $24,336.00 |
DisclosureSEC source: 0001562180-18-003983 · primarydocument.xml · nonDerivative · entry 10 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,510 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $80.80 to $81.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 20:24 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 200 | $79.45 | $15,890.00 |
DisclosureSEC source: 0001562180-18-003983 · primarydocument.xml · nonDerivative · entry 9 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,810 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $79.40 to $79.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 20:24 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 400 | $78.73 | $31,492.00 |
DisclosureSEC source: 0001562180-18-003983 · primarydocument.xml · nonDerivative · entry 8 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,010 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $78.40 to $79.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 20:24 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 900 | $77.88 | $70,092.00 |
DisclosureSEC source: 0001562180-18-003983 · primarydocument.xml · nonDerivative · entry 7 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,410 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $77.40 to $78.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.